Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Heart Failure Treatment Devices Market $15.2 Billion by 2027

The global market for heart failure treatment devices expected to reach $15.2 billion by 2027, growing at a CAGR of 4.0% over the forecast period, driven by increasing demand for advanced cardiac repair devices, rising incidences of cardiovascular disorders, and growing number of cardiac surgical procedures worldwide.

Global Heart Failure Treatment Devices Market

Heart failure (HF) is a disease which has a high mortality and morbidity. Its prevalence is increasing with a growing elderly population. Advanced HF is characterized by significantly impaired cardiac function and symptomatic limitation, despite optimal medical therapy.

  • Implantable cardioverter defibrillators and cardiac resynchronization therapy play an important role in the management of patients with advanced heart failure by treating life-threatening arrhythmias, and improving morbidity and survival.

Heart failure prevalence is more common in the elderly, with 10% of people over 75 being affected. For example, congestive heart failure has long been one of the most serious medical conditions in the United States.

  • In fact, in the United States alone, heart failure accounts for 6.5 million days of hospitalization each year. Therefore, there have been efforts to develop device-based therapies aimed at improving cardiac reserve and optimizing pump function to meet metabolic requirements.

Device therapy is now well established in pathways for treating patients with heart failure. The devices and diagnostics to treat heart failure include a wide range of ventricular assist devices (VADs), intra-aortic balloon catheters and pumps, artificial hearts, bypass systems, valve repair devices, and cardiac/hemodynamic monitoring systems, among others.

  • The CRT-D device combines both cardiac resynchronization therapy (CRT) and an implantable cardioverter defibrillator (ICD), where about 75% of patients without relief from symptoms with medication and have CRT, with or without an ICD, have improvement in their symptoms.

The global market for heart failure treatment devices research report provides market size ($million 2017 to 2027), market share analysis, growth trends and forecast (CAGR%, 2021 to 2027).

The global market for heart failure treatment devices segmented by product [therapeutic cardiac rhythm management devices (implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators), surgical procedure devices (vascular access site closure devices), others (heart valve replacement devices, heart valve repair devices), and geography.

  • Based on the products, the implantable cardioverter defibrillators (ICDs) sub-segment accounted for the largest share of the total market, whereas the vascular access site closure devices sub-segment anticipated to witness the fastest growth rate in the coming years.
  • ICDs have been in use for the last thirty years. Today, the technological advancements led to much improved devices with smaller generator that can be implanted under general anesthetic procedure.
    • According to the American Heart Association (AHA), the most common indication for ICD implantation in patients with HF is the primary prevention of sudden death. ICDs have been very useful in preventing sudden death in patients with known, sustained ventricular tachycardia or fibrillation.
      • These devices can be placed subcutaneously in the pectoral region where pacemakers are implanted, and the leads are placed endocardially in the venous system.
        • Newer-generation ICDs may have a dual function which includes the ability to serve as a pacemaker. The pacemaker feature would stimulate the heart to beat if the heart rate is detected to be too slow.
  • Vascular access site closure devices, or vascular closure devices (VCDs), are utilized to achieve hemostasis and prevent complications (e.g., bleeding and hematoma formation). 
    • Cardiovascular diseases (CVDs) are the leading causes of death throughout the world. According to the World Health Organization (WHO), approximately 17 million people die from CVDs every year, with over 75% of all CVD-related deaths occurring in low- and middle-income countries. 
      • The number of CVD-related procedures continues to increase as more people around the world gain access to improved therapies for the diagnosis and management of CVDs. Post-procedure, the risk of bleeding and/or complications at the vascular access site becomes a major obstacle to early patient discharge. 
    • The vascular closure devices are commonly used following percutaneous coronary intervention (PCI) with poor outcomes. The use of VCDs leads to reduced time to ambulation, increased patient comfort, and possible reduction in vascular complications as compared to manual compression. 

The global market for heart failure treatment devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for heart failure treatment devices report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for heart failure treatment devices and profiled in this report include Abbott Laboratories, Inc., Abiomed, Inc., Berlin Heart GmbH, Boston Scientific Corporation, CHF Solutions, Inc., Getinge AB, LivaNova plc, Medtronic plc, Teijin Medical Technologies, Ltd., and Teleflex Incorporated.

  • Product
    • Therapeutic Cardiac Rhythm Management Devices
      • Implantable Cardioverter Defibrillators (ICDs)
      • Cardiac Resynchronization Therapy Defibrillators (CRT-D)
    • Surgical Procedure Devices
      • Vascular Access Site Closure Devices  
    • Others
      • Heart Valve Replacement Devices
      • Heart Valve Repair Devices
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Abiomed, Inc.
    • Berlin Heart GmbH
    • Boston Scientific Corporation
    • CHF Solutions, Inc.
    • Getinge AB
    • LivaNova plc
    • Medtronic plc
    • Teijin Medical Technologies, Ltd.
    • Teleflex Incorporated

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]